Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aptevo Therapeutics Inc. - Common Stock (NQ:APVO)

6.750 +0.070 (+1.05%)
Streaming Delayed Price Updated: 9:42 AM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aptevo Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting
Preclinical data demonstrates inhibited tumor cell growth in vitro when paired with a T-cell engager bispecific SEATTLE, WA / ACCESSWIRE / November 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the... 
From Aptevo Therapeutics
Via AccessWire
News headline image
Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021
SEATTLE, WA / ACCESSWIRE / October 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology... 
From Aptevo Therapeutics
Via AccessWire
News headline image
Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated With Its Bispecific Antibody APVO436
SEATTLE, WA / ACCESSWIRE / October 26, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology... 
From Aptevo Therapeutics
Via AccessWire
News headline image
Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging
Lead Clinical Candidate, APVO436, Recently Showed Clinical Activity and Acceptable Safety Profile in Adults with Myelodysplastic Syndrome (MDS) Article outlines a new strategy to employ APVO436 for... 
From Aptevo Therapeutics
Via AccessWire
News headline image
Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Phase 1 study showed some patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) achieved a remission with APVO436 after failing 1-8 lines of prior therapies - Data was... 
From Aptevo Therapeutics
Via AccessWire
News headline image
Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights
SEATTLE, WA / ACCESSWIRE / August 12, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology... 
From Aptevo Therapeutics
Via AccessWire
News headline image
Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual Conference
SEATTLE, WA / ACCESSWIRE / July 16, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on... 
From Aptevo Therapeutics
Via AccessWire
News headline image
Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index
SEATTLE, WA / ACCESSWIRE / June 29, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on... 
From Aptevo Therapeutics
Via AccessWire
News headline image
Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia
Initiates Multi-Center, Multi-Arm Trial Using Active Dose Identified in the Dose Escalation Phase of the Trial SEATTLE, WA / ACCESSWIRE / May 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo")... 
From Aptevo Therapeutics
Via AccessWire
News headline image
Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia
- Dose Escalation Study of APVO436 Shows Favorable Safety Profile and No Severe Neutropenia, a Potentially Life-threatening Side Effect, Reported in a Significant Number of Patients Receiving... 
From Aptevo Therapeutics
Via AccessWire
Topics Death Intellectual Property
News headline image
Aptevo Therapeutics Reports First Quarter 2021 Financial Results
Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Dosing in Cohort 10 Ongoing SEATTLE, WA / ACCESSWIRE / May 11, 2021 / Aptevo... 
From Aptevo Therapeutics
Via AccessWire
News headline image
Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting
SEATTLE, WA / ACCESSWIRE / April 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its... 
From Aptevo Therapeutics
Via AccessWire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.